1. Flame retardant behaviour and physical-mechanical properties of polymer synergistic systems in rigid polyurethane foamsBranka Mušič, Nataša Knez, Janez Bernard, 2022, original scientific article Abstract: In the presented work, the influence of two flame retardants—ammonium polyphosphates and 2,4,6-triamino-1,3,5-triazine on the polyurethane foam (PUR) systems were studied. In this paper, these interactive properties are studied by using the thermal analytical techniques, TGA and DTA, which enable the various thermal transitions and associated volatilization to be studied and enable the connection of the results with thermal and mechanical analysis, as are thermal conductivities, compression and bending behavior, hardness, flammability, and surface morphology. In this way, a greater understanding of what the addition of fire retardants to polyurethane foams means for system flammability itself and, on the other hand, how this addition affects the mechanical properties of PUR may be investigated. It was obtained that retardants significantly increase the fire resistance of the PURs systems while they do not affect the thermal conductivity and only slightly decrease the mechanical properties of the systems. Therefore, the presented systems seem to be applicable as thermal insulation where low heat conductivity coupled with high flame resistance is required.
Keywords: flammability, polyurethane polymer, foams, thermal conductivity, mechanical properties, open access
Published in DiRROS: 08.06.2023; Views: 329; Downloads: 162
 Full text (10,71 MB)
This document has many files! More... |
2. Documenting metrological traceability as intended by ISO 15189:2012 : a consensus statement about the practice of the implementation and auditing of this norm elementMarc H. M. Thelen, Florent Vanstapel, Pika Meško-Brguljan, Bernard Gouget, Guilaine Boursier, Edward Barrett, Christos Kroupis, Maria Lohmander, Luděk Šprongl, Tatjana Vodnik, 2019, original scientific article Abstract: ISO15189:2012 requires medical laboratories to document metrological traceability of their results. While the ISO17511:2003 standard on metrological traceability in laboratory medicine requires the use of the highest available level in the traceability chain, it recognizes that for many measurands there is no reference above the manufacturer's selected measurement procedure and the manufacturer's working calibrator. Some immunoassays, although they intend to measure the same quantity and may even refer to the same reference material, unfortunately produce different results because of differences in analytical selectivity as manufacturers select different epitopes and antibodies for the same analyte. In other cases, the cause is the use of reference materials, which are not commutable. The uncertainty associated with the result is another important aspect in metrological traceability implementation. As the measurement uncertainty on the clinical samples is influenced by the uncertainty of all steps higher in the traceability chain, laboratories should be provided with adequate and appropriate information on the uncertainty of the value assignment to the commercial calibrators that they use. Although the between-lot variation in value assignment will manifest itself as part of the long-term imprecision as estimated by the end-user, information on worst-case to be expected lot-lot variation has to be communicated to the end-user by the IVD provider. When laboratories use ancillary equipment that potentially could have a critical contribution to the reported results, such equipment needs verification of its proper calibration and criticality to the result uncertainty could be assessed by an approach based on risk analysis, which is a key element of ISO15189:2012 anyway. This paper discusses how the requirement for metrological traceability as stated in ISO15189 should be met by the medical laboratory and how this should be assessed by accreditation bodies.
Keywords: laboratories, medical laboratory science, risk management, quality control, quality improvement, health care quality assurance, metrological traceability
Published in DiRROS: 22.10.2020; Views: 1241; Downloads: 274
 Link to file |
3. Worldwide perspectives on venom allergyPeter Korošec, Thilo Jakob, Harfi Harb, Robert Heddle, Sarah Karabus, Ricardo de Lima Zollner, Julij Šelb, Bernard Yu-Hor Thong, Fares Zaitoun, David B. K. Golden, Michael Levin, 2019, review article Abstract: Venom immunotherapy is the standard of care for people with severe reactions and has been proven to reduce risk of future anaphylactic events. There is a moral imperative to ensure production, supply and worldwide availability of locally relevant, registered, standardized commercial venom extracts for diagnosis and treatment. Insects causing severe immediate allergic reactions vary by region worldwide. The most common culprits include honeybees (Apis mellifera), social wasps including yellow jackets (Vespula and Dolichovespula), paper wasps (Polistes) and hornets (Vespa), stinging ants (Solenopsis, Myrmecia, Pachycondyla, and Pogonomyrmex), and bumblebees (Bombus). Insects with importance in specific areas of the world include the Australian tick (Ixodes holocyclus), the kissing bug (Triatoma spp), horseflies (Tabanus spp), and mosquitoes (Aedes, Culex, Anopheles). Reliable access to high quality venom immunotherapy to locally relevant allergens is not available throughout the world. Many current commercially available therapeutic vaccines have deficiencies, are not suitable for, or are unavailable in vast areas of the globe. New products are required to replace products that are unstandardized or inadequate, particularly whole-body extract products. New products are required for insects in which no current treatment options exist. Venom immunotherapy should be promoted throughout the world and the provision thereof be supported by health authorities, regulatory authorities and all sectors of the health care service.
Keywords: allergy and immunology, venoms, Hymenoptera, bee venoms, wasp venoms, insecta, ants hornet, bumblebee, mosquitoes, venom immunotherapy, immunologic desensitization
Published in DiRROS: 23.09.2020; Views: 1749; Downloads: 1040
Full text (313,42 KB)
This document has many files! More... |
4. |
5. |
